Volpara Health, a global health technology software leader providing an integrated platform for the delivery of personalized breast and lung care, further expanded its footprint in the US lung screening market with a strategic relationship with Seattle-based lung AI company RevealDx.

Getty Images


September 27, 2021 — Volpara Health, a global health technology software leader providing an integrated platform for the delivery of personalized breast and lung care, further expanded its footprint in the US lung screening market with a strategic relationship with Seattle-based lung AI company RevealDx. This follows Volpara's recent collaboration agreement with leading US lung imaging company Riverain Technologies.

Approximately, 20–30% of lung computed tomography (CT) exams reveal lung nodules which need to be characterized as benign or malignant. The workup typically may include a follow-up lung CT exam in a few months or a surgical biopsy. In addition, many lung nodules are found incidentally when CT exams are performed for other reasons, such as shortness of breath, chest pain, or injury.

Volpara Lung software—an advanced, integrated, and adaptable reporting, tracking, and risk assessment solution for lung cancer screening—enables patient management from scheduling to diagnosis. The software offers structured reporting, customisable reminders, and more than 40 statistical reports to monitor and track patients—critical for outreach to patients overdue for their screening or follow-up exams. Volpara Lung automatically collects and validates all the required data elements for successful submission to the American College of Radiology Lung Cancer Screening Registry for reimbursement.

RevealDx, formerly known as Mindshare Medical, is focused on improving lung cancer outcomes by delivering the most advanced, radiomics and AI-enabled, lung cancer decision-support software to drive the optimal clinical pathway for each patient based on automated analytics of each lung nodule. Its patented, CE-marked software product integrates with picture archiving and communication systems (PACS) and scores nodules found in lung CT, informing better clinical decision making. Early clinical data for RevealAI-Lung suggests that many cancers can be detected earlier by using the AI nodule analysis rather than waiting for a scan in a few months' time, while simultaneously reducing false positives, with potentially significant cost savings.

"When we acquired MRS, we entered the lung cancer screening market with practice management software covering about 8% of the US lung cancer screening market. Since then, the benefits of lung cancer screening using low-dose CT have become more widely accepted globally, with the US doubling the number of people eligible, and countries like Australia starting the process of scoping out nationwide programs. Despite the clear benefits of screening in reducing mortality, a major issue those programs face is the number of false positive nodules found in routine screening as well as incidental findings. That differentiation of nodules is exactly what RevealDx has been focusing on. We look forward to working closely with them to bring that technology to market as part of an integrated lung cancer screening platform," said Ralph Highnam, Ph.D., Group CEO of Volpara.

"Volpara has a solid market share in lung, and we look forward to working closely with them to fully integrate RevealDx's AI capabilities into a wider lung offering both here in the United States and into Australia and New Zealand. By informing precision medicine, our products will improve follow-up for millions of patients. The ability to diagnose early, inform treatments, and optimise the total cost of care will be a game-changer," said Chris Wood, RevealDx CEO.

For more information: www.volparahealth.com

Related Content

News | Computed Tomography (CT)

October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...

Time October 14, 2021
arrow
News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Breast Imaging

October 14, 2021 — Delphinus Medical Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) has ...

Time October 14, 2021
arrow
News | Radiology Business

October 14, 2021 — Intelerad Medical Systems, a global leader in medical image management solutions, today announced its ...

Time October 14, 2021
arrow
News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | Enterprise Imaging

October 8, 2021 — HealthLevel, Inc., innovator of Foundations, a business operations analytics platform for healthcare ...

Time October 08, 2021
arrow
News | MRI Breast

October 7, 2021 — An automated system that uses artificial intelligence (AI) can quickly and accurately sift through ...

Time October 07, 2021
arrow
News | Women's Health

October 6, 2021 — A commentary by Mayo Clinic Cancer Center researchers published in the Journal of Clinical Oncology ...

Time October 06, 2021
arrow
Subscribe Now